Product Description
A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02771730)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Emergent
Company Location: GAITHERSBURG MD 20879
Company CEO: Robert G. Kramer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: HIV Infections|Protein Deficiency|Eye Infections|Vaginal Discharge|Adenovirus Infections, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
14-I-0011 | P1 |
Completed |
Vaginal Discharge|Eye Infections|HIV Infections|Protein Deficiency|Adenovirus Infections, Human |
2019-04-08 |